-
China Resources Pharma Reports Strong Interim Results Amid COVID-19
•
China Resources Pharmaceutical Group Co., Ltd (HKG: 3320) has published its 2022 interim financial report, revealing a strong performance despite disruptions caused by COVID-19. During the period, the company generated revenues of HKD 12.57 billion ($1.6 billion), up 9.8% year-on-year (YOY), and net profits of HKD 6.168 billion ($785.7 million),…
-
Sciwind Biosciences Partners with SynerK for siRNA Therapeutics Development
•
Hangzhou Sciwind Biosciences Co., Ltd has announced a research partnership with SynerK Inc. The collaboration aims to jointly discover and develop new therapeutics based on small interfering RNA (siRNA) technology to address unmet medical needs in the treatment of liver and metabolic diseases. Financial details of the partnership were not…
-
Arctic Vision Administers First Injection of ARVN001 for Uveitis Macular Edema
•
China-based ophthalmic therapies developer Arctic Vision has announced the first injection of triamcinolone acetonide suprachoroidal injection suspension (ARVN001) in a patient with uveitis macular edema (UME) at the Boao Super Hospital in Hainan’s medical pilot zone. This marks the first application of suprachoroidal injection therapy in Lecheng, facilitated by the…
-
Synthgene Partners with Micor&Nano for Comprehensive Solutions in Nucleic Acid Drugs
•
China-based Jiangsu Synthgene Biotechnology Co., Ltd has entered into a partnership with compatriot firm Micor&Nano (Shanghai) Technology Co., Ltd. The collaboration, focused on nucleic acid drugs, aims to provide comprehensive solutions ranging from raw materials to equipment and processes. Partnership Focus and ObjectivesSynthgene, a leading upstream raw material supplier for…
-
ThunderBio Secures Funding from Guangzhou LBP for PCR Innovation
•
ThunderBio Innovation Limited, a specialist in droplet microfluidics and molecular diagnostics based in Zhejiang, has raised an undisclosed amount of funding from Guangzhou LBP Medicine Science & Technology Co., Ltd. The collaboration will focus on advancing digital polymerase chain reaction (PCR) technology, including product research and development (R&D), manufacturing, and…
-
Fujian Cosunter Receives NMPA Approval for COVID-19 Drug Candidate GST-HG171
•
China-based Fujian Cosunter Pharmaceutical Co., Ltd (SHE: 300436) has announced that it has received approval from the National Medical Products Administration (NMPA) to conduct a clinical study for its Category 1 drug candidate, GST-HG171, in adult patients with mild/common COVID-19. This marks a significant step forward in the development of…
-
Everest Medicines Gains CDE Approval for EVER001 Phase Ib Study
•
China-based biotech Everest Medicines (HKG: 1952) has announced that it has received approval from the Center for Drug Evaluation (CDE) in China to conduct a Phase Ib clinical study assessing the safety, efficacy, pharmacokinetics, and pharmacodynamics of its EVER001. The drug candidate, a next-generation covalent reversible Bruton’s tyrosine kinase (BTK)…
-
Boston Scientific Completes First Surgery with RotaPro in China
•
US-based Boston Scientific Corporation (NYSE: BSX) has announced the completion of the first surgery using its RotaPro rotational atherectomy system at Ruijin Hospital’s Hainan Hospital (Boao research-oriented hospital) branch. This procedure marks the first clinical application of the product in China, facilitated by the “first pilot, first trial” scheme, which…
-
Sihuan Pharmaceutical Reports Decline in Revenues Amid COVID-19 Lockdowns
•
China’s Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) has released its 2022 interim report for the first six months of the year. The firm reported RMB 1.464 billion ($204.3 million) in revenues, down 23.2% year-on-year (YOY). The decline was attributed to COVID-19 related lockdowns in the domestic market. Business Segment…
-
Shuangcheng Pharma Licenses US Rights for Paclitaxel Injection to Meitheal
•
China’s Hainan Shuangcheng Pharmaceutical Co., Ltd (SHA: 002693) has announced a licensing and supply agreement with US-based Meitheal Pharmaceuticals, Inc., and compatriot firm Hong Kong King-Friend Industrial Co., Ltd. The agreement grants the two companies exclusive rights to Shuangcheng’s paclitaxel for injection (albumin-bound, 100mg/vial) in the US market. Meitheal will…
-
HEC Pharma Overturns Patent Decision Against Novartis’ Gilenya
•
China-based generics firm HEC Pharma has managed to overturn a previous final decision in a patent dispute with Swiss pharmaceutical giant Novartis AG (NYSE: NVS) over the multiple sclerosis blockbuster drug Gilenya (fingolimod). In January 2022, the US Court of Appeals for the Federal Circuit (CAFC) had dismissed an appeal…
-
Nerviano Medical Sciences Collaborates with Merck on PARP1 Inhibitor NMS-293
•
Italy-based Nerviano Medical Sciences S.r.l. (NMS), which is 90% owned by Chinese investment fund SARI under a deal that closed in 2018, has unveiled a collaboration and licensing deal with Germany-based Merck Healthcare KGaA. The agreement grants Merck global rights to develop and commercialize the poly (ADP-ribose) polymerase 1 (PARP1)…
-
Moderna’s CMO Expresses Eagerness to Bring mRNA Vaccines to China
•
The Chief Medical Officer (CMO) of US-based Moderna Inc. (NASDAQ: MRNA), Paul Burton, has been reported as saying that the company is “eager” to bring its mRNA-based COVID-19 vaccines to China. According to sources, Moderna’s chief executive Stephane Bancel disclosed last week that the company has engaged in talks with…
-
Novartis Faces Setback in US Patent Battle Over Multiple Sclerosis Drug Gilenya
•
Swiss pharmaceutical giant Novartis AG (SWX: NOVN) has encountered its latest and potentially final setback in the fight to maintain a key patent covering the multiple sclerosis drug Gilenya (fingolimod) in the United States. The company announced that the US Court of Appeals for the Federal Circuit (CAFC) had denied…
-
Sino Biopharmaceutical Licenses Lanifibranor for NASH Treatment from Inventiva
•
China-based Sino Biopharmaceutical Ltd (HKG: 1177) has announced that its subsidiary, Jiangsu Chia Tai Tianqing Pharmaceutical Co., Ltd (CTTQ), has entered into a licensing agreement with France-headquartered Inventiva (NASDAQ: IVA). The deal grants CTTQ development, manufacturing, and commercialization rights to lanifibranor, Inventiva’s drug for the treatment of nonalcoholic steatohepatitis (NASH)…
-
Hengrui Medicine’s Dexmedetomidine Nasal Spray Gains Priority Review
•
China’s Center for Drug Evaluation (CDE) has indicated that Hengrui Medicine Co., Ltd’s (SHA: 600276) dexmedetomidine hydrochloride nasal spray has been awarded priority review status. The drug is filed for approval as a preoperative sedation in children, such as for general anesthesia in pediatric patients. Drug Overview and Market ContextDexmedetomidine,…
-
Menarini and OrigiMed Partner on Pan-Cancer Single-Cell Diagnostic Platform
•
Italy’s Menarini Group has formed a strategic partnership with China-based precision medicine firm OrigiMed to co-develop a pan-cancer single-cell molecular diagnostic innovation platform. The collaboration leverages the respective platform advantages and integrates resources to work on a single-cell clinical molecular diagnosis project based on high-throughput next-generation sequencing technology. Moving forward,…
-
Jenscare Scientific Set for IPO to Fund Structural Heart Disease Solutions
•
Jenscare Scientific Co., Ltd., a structural heart disease intervention device maker based in Ningbo, is set to make an initial public offering (IPO) of 8.08 million shares on the Hong Kong Stock Exchange. The IPO is priced at HKD 28.8 ($3.67) per share, raising a total of HKD 232.6 million.…
-
InnoCare Pharma’s IPO Raises $411M for Drug R&D and Platform Upgrade
•
China-based InnoCare Pharma (HKG: 9969) has completed an initial public offering (IPO) of 265 million shares on the Shanghai Stock Exchange’s Sci-Tech Innovation Board (STAR) at RMB 11.03 per share ($1.55). The offering raised RMB 2.92 billion ($411 million), with proceeds allocated towards new drug research and development (R&D), upgrading…
-
Humanwell’s Generic Clobazam Approved for Lennox-Gastaut Syndrome in China
•
China-based Yichang Humanwell Pharmaceutical Co., Ltd’s generic version of Sanofi’s clobazam (trade name: Frisium) has been approved by the National Medical Products Administration (NMPA) for use as a combination therapy for seizures in patients with Lennox-Gastaut syndrome (LGS) aged two years and older. This marks the first availability of this…
